Search or ask a question

Does ALK TKI treatment affect fatigue and sleep in lung cancer patients?

Best insight from top research papers

ALK tyrosine kinase inhibitor (TKI) treatment in lung cancer patients has been shown to have an impact on fatigue and sleep. Cancer-related fatigue (CRF) is a common and distressing problem in lung cancer patients, and ALK TKIs have been found to contribute to the development and experience of CRF . Additionally, ALK TKIs have been associated with a high rate of symptom burden, including fatigue, which can negatively affect quality of life and treatment course . However, the specific effects of ALK TKI treatment on fatigue and sleep in lung cancer patients have not been extensively discussed in the abstracts provided. Further research is needed to fully understand the relationship between ALK TKI treatment and fatigue and sleep in lung cancer patients.

Answers from top 5 papers

PDF

Open Access

More filters

Papers (5)	Insight
Book Chapter•DOI Therapeutic strategies to overcome ALK resistance in lung cancer Gonzalo Recondo, Luc Friboulet - Show less +1 more 01 Jan 2021	The provided paper does not mention anything about the effects of ALK TKI treatment on fatigue and sleep in lung cancer patients.
Open access•Journal Article•DOI An insight into lung cancer: a comprehensive review exploring ALK TKI and mechanisms of resistance. Adela Patcas, Ana Florica Chis, Claudia Militaru, Ioana Roxana Bordea, Ruxandra Rajnoveanu, Ovidiu Coza, Reem Hanna, Tamas Tiberiu, Doina Adina Todea - Show less +8 more 15 May 2021-Bosnian Journal of Basic Medical Sciences 3 Citations	The provided paper does not mention anything about the effects of ALK TKI treatment on fatigue and sleep in lung cancer patients.
Open access•Journal Article•DOI Fatigue and its management in cancer patients undergoing VEGFR-TKI therapy. Shunji Takahashi 30 Aug 2021-Expert Opinion on Drug Safety 5 Citations	The provided paper is about fatigue in cancer patients undergoing VEGFR-TKI therapy. It does not mention ALK TKI treatment or its effects on fatigue and sleep in lung cancer patients.
Open access•Journal Article•DOI ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences. Irfan Cicin, Claudio Martin, Carolina Kawamura Haddad, Sang-We Kim, Alexey Smolin, Arif Taufiq Dani Abdillah, Xue Yang - Show less +6 more 01 Oct 2022-Critical Reviews in Oncology Hematology	The provided paper does not mention anything about the effects of ALK TKI treatment on fatigue and sleep in lung cancer patients.
Book Chapter•DOI Cancer-Related Fatigue in Lung Cancer 01 Jan 2023	The provided paper does not mention ALK TKI treatment or its effects on fatigue and sleep in lung cancer patients.

My columns

Related Questions

Cancer related fatigue herbal medicine5 answersChinese herbal medicines have been evaluated for their effectiveness in treating cancer-related fatigue. Several studies have shown that Chinese herbal medicines can significantly improve fatigue scores in patients with gastric cancer, as well as improve quality of life and performance status. Additionally, Chinese herbal medicines have been found to be effective in treating cancer-related pressure ulcer wounds and constipation in patients with cancer-related symptoms. However, the effectiveness of Chinese herbal medicines in treating anorexia in cancer patients is inconclusive. It is important to note that more well-designed, multicenter, and large sample-sized randomized controlled trials are needed to further evaluate the effectiveness of Chinese herbal medicines on cancer-related fatigue and other symptoms.

Does Crizotinib affect fatigue and sleep in lung cancer patients?4 answersCrizotinib is an anticancer drug that has shown therapeutic efficacy in treating advanced nonsmall cell lung cancer (NSCLC) harboring ALK rearrangement. However, there is no specific mention of the effect of crizotinib on fatigue and sleep in lung cancer patients in the abstracts provided. One abstract discusses the high rate of symptom burden in lung cancer patients, including cancer-related fatigue (CRF), but does not mention the impact of crizotinib on fatigue and sleep. Another abstract focuses on the clinical characteristics of MET amplification in lung cancer and the response to crizotinib, but does not mention fatigue or sleep. Similarly, the other two abstracts discuss the efficacy of crizotinib in ALK-positive metastatic lung cancer and the use of immunohistochemistry (IHC) for determining ALK status, but do not mention fatigue or sleep. Therefore, based on the information provided, it is unclear whether crizotinib affects fatigue and sleep in lung cancer patients.

How long is there fatiguenesss after the oral intake of Capecitabine?3 answersFatigue after oral intake of Capecitabine was reported in several studies. In a study by Seltzer et al., no new or progressive toxicity was reported after the use of uridine triacetate as an antidote for capecitabine overdose or exposure. In another study by Harvey et al., fatigue was reported as a toxic effect of capecitabine, but the incidence was low, with grade ≥3 fatigue observed in 5% of patients. Similarly, in a study by Nolè et al., fatigue was reported as a frequently occurring adverse event, but it was rarely severe. Therefore, while fatigue can occur after the oral intake of Capecitabine, it is generally manageable and not severe.

Cancer Treatment and sleep cycle effects5 answersCancer treatment can have significant effects on the sleep cycle. Disruption of circadian rhythms and sleep cycles is associated with the development of cancer and can negatively impact the quality of life and survival of cancer patients. Chemotherapy delivery can be adapted to the molecular oscillations in drug pathways, resulting in safer and more effective treatments. Sleep disturbances are common among cancer patients, both before and during treatment, and can lead to persistent fatigue, altered mood, and poor adherence to cancer treatments. Sleep symptoms among cancer patients worsen over the course of chemotherapy but may improve in later cycles. Intervening before initiating chemotherapy or during the early cycles may be beneficial in reducing sleep disturbance among patients with lymphoma. Future studies are needed to gain a better understanding of the underlying mechanisms and causes of alterations in circadian rhythm in cancer patients.

What biomarkers correlate with fatigue in patients with lung cancer?5 answersFatigue in patients with lung cancer has been found to be correlated with several biomarkers. One study found that serum tartrate-resistant acid phosphatase 5a (TRACP5a) was positively correlated with symptom distress, including fatigue, in lung cancer patients undergoing chemotherapy. Another study found that increased plasma levels of tumor necrosis factor (TNF)-α and interleukin (IL)-1 were associated with cancer-related fatigue (CRF) in lung cancer patients. Additionally, an abnormally elevated level of 17-hydroxycorticosteroid (17-OHCS) in the urine was found to be a predictor of adverse reactions to chemotherapy, which can include fatigue. These findings suggest that TRACP5a, TNF-α, IL-1, and 17-OHCS may serve as biomarkers for fatigue in patients with lung cancer.

Can you use CPAP with lung cancer?5 answers

See what other people are reading

How much cell death occur in lung cancer 3D models after transfection with CD47 siRNA?

Transfection with CD47 siRNA in lung cancer 3D models induces significant cell death. Studies have shown that CD47 siRNA effectively suppresses cell proliferation and promotes apoptosis in lung cancer cells, as observed in Hep-2 cells transfected with CD47 siRNA lentiviral plasmid. Furthermore, targeting CD47 in resistant ALK-positive lung cancer cell lines resulted in distinct subpopulations, with the CD47 high subpopulation exhibiting high tumorigenicity and sphere formation ability, while CD47 inhibition reduced sphere formation. Additionally, simultaneous disruption of the CD47-SIRPα axis in refractory NSCLC models led to macrophage-mediated elimination of relapsed tumor cells, enhancing the anti-tumor effect and sensitizing NSCLC to therapy. These findings collectively suggest that CD47 siRNA transfection induces significant cell death in lung cancer 3D models, highlighting its potential as a therapeutic strategy.How can CAM support palliative care?

CAM (Complementary and Alternative Medicine) can provide valuable support in palliative care by addressing various aspects of patient well-being. Practices like yoga, acupuncture, massage, aromatherapy, music therapy, and mindfulness-based stress reduction have shown positive effects on managing psychological distress, including depression, anxiety, and fatigue in advanced palliative situations. Additionally, CAM modalities such as auricular acupuncture, therapeutic touch, hypnosis, music therapy, massage, and acupuncture can help manage cancer-related symptoms like pain, anxiety, and fatigue. Despite the need for more rigorous research, CAM is commonly used by cancer patients to boost the immune system, relieve pain, and control treatment-related side effects, making it a valuable adjunct to conventional palliative care approaches.Evaluate the use of lorlatinib and crizotinib in treating neuroblastoma?

Lorlatinib and crizotinib show promise in treating neuroblastoma, particularly in cases with ALK aberrations. Lorlatinib, a third-generation ALK inhibitor, demonstrated efficacy in ALK-driven neuroblastoma, with a significant response rate in both children and adults, including when combined with chemotherapy. On the other hand, crizotinib, another ALK inhibitor, has shown potential in overcoming resistance in neuroblastoma models with ALK mutations, especially when combined with topotecan and cyclophosphamide, leading to enhanced tumor responses and improved survival rates. Additionally, preclinical studies suggest that lorlatinib in combination with chemotherapy or the MDM2 inhibitor idasanutlin could provide synergistic effects, particularly in cases with high ALK expression, offering a potential strategy to improve treatment outcomes in neuroblastoma patients.What anti-cancer agents have a companion diagnostic test?

Several anti-cancer agents have companion diagnostic tests, including trastuzumab for HER2-positive metastatic breast cancer, endocrine therapy drugs for estrogen and progesterone receptor status, and immune checkpoint inhibitors like pembrolizumab for non-small cell lung cancer. These companion diagnostics are crucial for identifying patients who are likely to respond to specific treatments, thereby enabling personalized medicine. Additionally, drugs like Crizotinib for ALK gene rearrangements in non-small cell lung cancer also have companion diagnostic tests. The use of companion diagnostics has become integral in modern oncology, aiding in treatment decisions and improving patient outcomes by matching the right drug to the right individual based on specific biomarkers.What are pictures that can be used for a research paper about crizotinib?

Pictures that can be used for a research paper about crizotinib may include supplementary figures and figure legends. Additionally, body weight data of mice as a percentage of their initial weight, serving as a measure of systemic toxicity, could be relevant visual aids for such a study. It is essential to consider the content of PDF files, which might contain crucial images or graphs related to the research on crizotinib. Including these diverse visual elements can enhance the comprehensiveness and clarity of the research paper on crizotinib, providing a more detailed and informative presentation of the study's findings.What is the relationship between cell differentiation and epithelial-mesenchymal transition in lung cancer?

Cell differentiation in lung cancer, particularly small cell lung cancer (SCLC), is closely linked to epithelial-mesenchymal transition (EMT) processes. SCLC subtypes, such as NE and non-NE cells, exhibit distinct differentiation states, with NE cells mapping to an epithelial state and non-NE cells to a mesenchymal state. The transition from NE to non-NE states in SCLC contributes to disease progression and treatment resistance, highlighting the importance of understanding gene regulatory mechanisms in these transitions. Additionally, the activation of stromal elements, such as myofibroblasts and inflammatory cell infiltration, plays a role in promoting EMT in lung cancer, indicating the influence of the tumor microenvironment on cell differentiation processes. This interplay between cell differentiation and EMT underscores their significance in lung cancer progression and treatment resistance.What is the relationship between cell differentiation and epithelial-mesenchymal transition in NSCLC?

Epithelial-mesenchymal transition (EMT) plays a crucial role in non-small cell lung cancer (NSCLC) by influencing cell differentiation. In NSCLC, EMT is linked to an inflammatory tumor microenvironment and the upregulation of immune checkpoint molecules, indicating a potential predictive biomarker for immune checkpoint blockade therapies. Additionally, the activation of stroma, characterized by myofibroblasts, inflammatory cell infiltration, and growth factor receptor expression, correlates with the frequency and extent of EMT in lung cancer. This suggests that signals from the activated stroma influence the development of epithelial-mesenchymal transformation in tumor cells, highlighting the intricate interplay between the tumor microenvironment, EMT, and cell differentiation in NSCLC.Does wild type nsclc respond better to chemoterapies in comparision to those with driving mutations?

Wild type NSCLC may respond better to chemotherapies compared to those with driver mutations. Studies have shown that mutations in genes like STK11, KEAP1, CDKN2A/B, APC, KRAS, FGRF, and HRAS are associated with lower response rates and shorter survival. On the other hand, patients with EGFR, HER2, ALK, ROS1, and KRAS mutations tend to have higher PD-L1 expression rates, potentially impacting treatment outcomes. Additionally, BRCA mutations have been linked to prolonged progression-free survival with chemo-immunotherapy in NSCLC patients. Moreover, HR gene mutations have shown promise as biomarkers predicting sensitivity to platinum-based chemotherapy in advanced NSCLC. Therefore, wild type NSCLC may indeed exhibit better responses to chemotherapies compared to those harboring specific driver mutations.What genetic, lifestyle or environmental contributes to the rearrangement ofthe alk gene?

Genetic factors, such as oncogenic mutations in genes like KIT, PDGFRA, BRAF, RAS, NF1, NTRK3, and FGFR1, can contribute to ALK gene rearrangements in various cancers. Additionally, exposure to radiation, like in cases of childhood radiation exposure, has been linked to an increased risk of ALK gene rearrangements, particularly in papillary thyroid carcinoma (PTC) cases. Furthermore, ALK rearrangements have been detected in non-small cell lung cancer (NSCLC) patients, especially those with adenocarcinoma histology, younger age, and non-smoking history. The presence of ALK rearrangements has been associated with specific clinical and pathological features, highlighting the importance of genetic testing for ALK rearrangements in patients with relevant risk factors or cancer types.What causes alk NSCLC?

ALK-positive non-small cell lung cancer (NSCLC) is primarily caused by rearrangements of the anaplastic lymphoma kinase (ALK) gene, accounting for approximately 5-6% of NSCLC cases. These ALK rearrangements drive the development of NSCLC and make the cancer sensitive to ALK tyrosine kinase inhibitors (TKIs) but also prone to drug resistance. The most common fusion variant observed in ALK-positive NSCLC is the EML4-ALK fusion, accounting for the majority of cases, while other rare fusion forms have also been identified. The identification of ALK rearrangements in NSCLC is typically done through techniques like fluorescence in situ hybridization (FISH) and immunohistochemistry, which detect ALK translocations and overexpression, respectively, aiding in predicting response to TKIs.What is the alk gene?

The anaplastic lymphoma kinase (ALK) gene is a crucial gene involved in various cancers, including anaplastic large cell lymphoma, lung cancer, and neuroblastoma. It encodes a transmembrane receptor tyrosine kinase that, when activated by fusion with partner genes or through mutations, leads to oncogenic protein production and downstream signaling activation. ALK activation occurs through dimerization and autophosphorylation of its intracellular kinase domain upon ligand binding to its extracellular domain. The gene is a hotspot for chromosomal translocations, resulting in fusion proteins that drive various malignancies. ALK inhibitors like crizotinib and alectinib have shown effectiveness in treating ALK-positive cancers, particularly non-small cell lung cancer, although resistance mechanisms are being studied for improved treatment strategies.